By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Reaction Biology has reeled in a $1.2 million small business innovation research grant from the National Cancer Institute that it will use to expand an epigenetics-related drug discovery screening platform, the company said today.

The Malvern, Pa.-based firm plans to use the two-year grant to expand its Methyltransferase HotSpotSM drug discovery screens from 14 to 35 or more, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.